Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 6.03
(-3.51%)
USD 6.03
(-3.51%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 36.32 Million USD | -15.43% |
| 2022 | 42.95 Million USD | -46.44% |
| 2021 | 80.18 Million USD | -20.54% |
| 2020 | 100.91 Million USD | -0.26% |
| 2019 | 101.18 Million USD | 1.75% |
| 2018 | 99.44 Million USD | 433.08% |
| 2017 | 18.65 Million USD | 93.23% |
| 2016 | 9.65 Million USD | -1.44% |
| 2015 | 9.79 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 36.8 Million USD | 0.65% |
| 2024 Q1 | 36.56 Million USD | 0.66% |
| 2023 Q4 | 36.32 Million USD | 0.67% |
| 2023 FY | 36.32 Million USD | -15.43% |
| 2023 Q3 | 36.08 Million USD | 7.49% |
| 2023 Q1 | 33.26 Million USD | -22.54% |
| 2023 Q2 | 33.56 Million USD | 0.9% |
| 2022 Q2 | 79.85 Million USD | -1.08% |
| 2022 Q4 | 42.95 Million USD | 0.65% |
| 2022 Q3 | 42.67 Million USD | -46.56% |
| 2022 FY | 42.95 Million USD | -46.44% |
| 2022 Q1 | 80.72 Million USD | 0.67% |
| 2021 Q4 | 80.18 Million USD | -25.08% |
| 2021 Q2 | 107.09 Million USD | 4.96% |
| 2021 FY | 80.18 Million USD | -20.54% |
| 2021 Q3 | 107.03 Million USD | -0.06% |
| 2021 Q1 | 102.03 Million USD | 1.1% |
| 2020 Q3 | 100.99 Million USD | -0.06% |
| 2020 Q2 | 101.05 Million USD | -0.07% |
| 2020 Q1 | 101.11 Million USD | -0.07% |
| 2020 FY | 100.91 Million USD | -0.26% |
| 2020 Q4 | 100.91 Million USD | -0.08% |
| 2019 Q4 | 101.18 Million USD | -0.06% |
| 2019 Q2 | 101.67 Million USD | 0.01% |
| 2019 Q1 | 101.66 Million USD | 2.24% |
| 2019 FY | 101.18 Million USD | 1.75% |
| 2019 Q3 | 101.24 Million USD | -0.43% |
| 2018 FY | 99.44 Million USD | 433.08% |
| 2018 Q4 | 99.44 Million USD | 399.95% |
| 2018 Q1 | 20.04 Million USD | 7.46% |
| 2018 Q2 | 19.96 Million USD | -0.38% |
| 2018 Q3 | 19.89 Million USD | -0.4% |
| 2017 FY | 18.65 Million USD | 93.23% |
| 2017 Q4 | 18.65 Million USD | -5.5% |
| 2017 Q3 | 19.74 Million USD | 103.3% |
| 2017 Q2 | 9.71 Million USD | 0.29% |
| 2017 Q1 | 9.68 Million USD | 0.29% |
| 2016 Q4 | 9.65 Million USD | 0.0% |
| 2016 FY | 9.65 Million USD | -1.44% |
| 2015 FY | 9.79 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | 0.583% |
| Dynavax Technologies Corporation | 256.91 Million USD | 85.862% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 12.532% |
| Perrigo Company plc | 4.07 Billion USD | 99.108% |
| Illumina, Inc. | 2.26 Billion USD | 98.394% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.896% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3532.3% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.62% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.745% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 79.095% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.656% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -34.579% |
| Waters Corporation | 2.35 Billion USD | 98.458% |
| Biogen Inc. | 7.33 Billion USD | 99.505% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 4.674% |
| Evolus, Inc. | 126.54 Million USD | 71.297% |
| Adicet Bio, Inc. | 17.7 Million USD | -105.18% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 15.855% |
| bluebird bio, Inc. | 330.32 Million USD | 89.004% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 93.285% |
| FibroGen, Inc. | 170.45 Million USD | 78.691% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.672% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -73.925% |
| Homology Medicines, Inc. | 44.05 Million USD | 17.549% |
| Geron Corporation | 85.89 Million USD | 57.714% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.485% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 91.839% |
| Myriad Genetics, Inc. | 145 Million USD | 74.95% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -2782.778% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 68.51% |
| Zoetis Inc. | 6.8 Billion USD | 99.466% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -725.148% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 98.324% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 96.797% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 95.507% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 97.501% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 37.236% |
| Verastem, Inc. | 41.55 Million USD | 12.595% |
| Nektar Therapeutics | 230.4 Million USD | 84.235% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 80.51% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1081.62% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 97.4% |
| OPKO Health, Inc. | 326.56 Million USD | 88.877% |
| Exelixis, Inc. | 189.94 Million USD | 80.877% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 91.521% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -23954.967% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 73.757% |
| Imunon, Inc. | 1.13 Million USD | -3088.205% |
| Blueprint Medicines Corporation | 774.12 Million USD | 95.308% |
| Insmed Incorporated | 1.2 Billion USD | 96.983% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.577% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 36.262% |
| TG Therapeutics, Inc. | 110.79 Million USD | 67.216% |
| Incyte Corporation | 38.28 Million USD | 5.13% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 95.861% |